Pharmaceuticals

Next Generation Antibody Drug Market 2025–2029: Tracking 15.4% CAGR Toward $29.08 Billion in Revenue

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation antibody drug market from 2025–2034 with trusted insights from The Business Research Company

How Will The Next Generation Antibody Drug Market Size Evolve Between Now And 2029?

The next generation antibody drug market has experienced swift expansion in recent years. This market is forecast to expand from $14.26 billion in 2024 to $16.4 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.0%. The expansion observed historically stems from factors such as increasing demand for targeted therapies, the rising prevalence of cancer, the growing adoption of immuno-oncology therapies, an increasing focus on autoimmune diseases, and growing regulatory support.

The next generation antibody drug market size is anticipated to undergo swift expansion in the coming years. It is projected to climb to $29.08 billion by 2029, achieving a compound annual growth rate (CAGR) of 15.4%. This projected growth can be attributed to several factors, including an increasing demand for personalized medicine, expanding drug pipelines, enhanced healthcare awareness, more frequent research collaborations, and a growing elderly population. Prominent trends for the forecast period encompass breakthroughs in antibody-drug conjugates, technological advancements in bispecific antibodies, the adoption of next-generation sequencing, progress in protein engineering, and the integration of gene therapy.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

Which Key Drivers Are Powering Growth In The Next Generation Antibody Drug Market?

A growing emphasis on personalized medicine is anticipated to drive the expansion of the next-generation antibody-drug market in the future. This medical strategy customizes treatments and healthcare plans for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices, thereby providing more effective and precise therapies. The rise of personalized medicine stems from progress in genomic sequencing, which facilitates more accurate diagnoses and specific treatment approaches. Next-generation antibody drugs contribute to the heightened focus on personalized medicine by enabling the creation of targeted therapies specifically adapted to patients’ genetic profiles and disease attributes, leading to better effectiveness and fewer side effects. As an example, in February 2024, data from the Personalized Medicine Coalition, a US organization advocating for personalized medicine, indicated that in 2023, the United States Food and Drug Administration (FDA) authorized 16 new personalized treatments for individuals with rare diseases, an increase from 6 approvals in 2022. Consequently, the amplified attention on personalized medicine is a key driver for the next-generation antibody drug market.

How Is The Global Next Generation Antibody Drug Market Structured By Key Segments?

The next generation antibody drug market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies

3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration, Oral Formulations, Transdermal Delivery Systems

4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications

5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies

3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

What Future-Focused Trends Are Anticipated In The Next Generation Antibody Drug Market?

Companies operating within the next generation antibody drug market are prioritizing the development of innovative solutions, such as antibody-drug conjugates, to improve targeted cancer therapies, enhance therapeutic efficacy, and decrease systemic toxicity. An antibody-drug conjugate (ADC) is a targeted cancer treatment that links a monoclonal antibody with a cytotoxic drug using a linker to specifically deliver the drug to tumor cells while minimizing harm to healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology company, partnered with Duality Biologics (Suzhou) Co. Ltd., a China-based pharmaceutical company, and secured a Fast Track designation from the U.S. Food and Drug Administration (FDA) for their next-generation antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, intended for treating platinum-resistant ovarian cancer. This drug leverages DualityBio’s innovative DITAC (Duality Immune Toxin Antibody Conjugates) platform, which merges a highly potent cytotoxic payload with a monoclonal antibody, enabling precise delivery of treatment directly to cancer cells. BNT325/DB-1305’s capacity to accurately target cancer cells while limiting damage to healthy tissues is a crucial advantage for elevating treatment efficacy and lowering side effects.

Which Companies Hold A Competitive Edge In The Next Generation Antibody Drug Market?

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

Which Region Is Expected To Lead The Next Generation Antibody Drug Market In The Next Few Years?

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in the next generation antibody drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24335&type=smp

Browse Through More Reports Similar to the Global Next Generation Antibody Drug Market 2025, By The Business Research Company

Next Generation Personalized Beauty Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-personalized-beauty-global-market-report

Next Generation Personalized Beauty Market 2025

https://www.thebusinessresearchcompany.com/report/next-generation-personalized-beauty-market

Next Generation Firewall Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795